Impacts of multiple-field irradiation and boron concentration on the treatment of boron neutron capture therapy for non-small cell lung cancer

Authors

  • C. Geng Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • C. Gong Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • D. Chen Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • D. Shu Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • H. Yu Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • S. Hang Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
  • X. Tang Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
Abstract:

Background: Boron neutron capture therapy (BNCT) is a radiotherapy that combines biological targeting and high linear energy transfer. A potential therapeutic approach for non-small cell lung cancer (NSCLC) is considered. However, dose in lung tumor is not homogeneous, and it will reduce the effect of BNCT treatment. In order to improve the dose distribution of BNCT, the multi-field irradiation strategy and its effects need to be explored. Materials and Methods: Common NSCLC model was defined in Chinese hybrid reference phantom and the boron concentration in skin and tumor varied from 6 to 18 ppm and from 30 to 65 ppm, respectively. Monte Carlo method for dose distribution calculation was used. Accelerator-based neutron source called “Neuboron source” was used and multi-field source irradiation plans were designed to optimize the dose distribution. Results: Under one-field irradiation, it was not feasible to perform BNCT, because the skin dose is unlikely to meet its dose limit. Under two- and three-field irradiation, the uniformity of tumor dose was improved and the maximum dose to organs at risk (OARs) decreased. If boron concentration in skin was between 6-18 ppm, BNCT was feasible with the boron concentration in tumor reaching about 57-60 ppm for two-field irradiation and 41-45 ppm for three-field irradiation, respectively. Conclusion: The multi-field irradiation plan could improve the dose distribution and the feasibility of BNCT for NSCLC. Theoretical distributions of Boron-10 were obtained to meet the treatable requirement of BNCT, which could provide a reference for NSCLC using BNCT in future multiple-field irradiation.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

impacts of multiple-field irradiation and boron concentration on the treatment of boron neutron capture therapy for non-small cell lung cancer

background: boron neutron capture therapy (bnct) is a radiotherapy that combines biological targeting and high linear energy transfer. a potential therapeutic approach for non-small cell lung cancer (nsclc) is considered. however, dose in lung tumor is not homogeneous, and it will reduce the effect of bnct treatment. in order to improve the dose distribution of bnct, the multi-field irradiation...

full text

Investigation the potential of Boron neutron capture therapy (BNCT) to treat the lung cancer

Introduction: Boron neutron capture therapy (BNCT) is recommended to treat the glioblastoma tumor. It is well known that neuron beams are more effective treatment than photon beams to treat hypoxia tumors due to interaction of neutron with nucleus and production of heavy particles such as 7Li and alpha particle. In this study to evaluate the suitability of BNCT for treating of ...

full text

Boron neutron capture therapy for cancer.

*1102 Expression of Neural Cell Adhesion Molecule-related Sialoglycoprotein in Small Cell Lung Cancer and Neuroblastoma Cell Lines 1169 and CHP-212. C. E. C. Kitty Moolenaar. Egbert J. Muller, Dick J. Schol, Carl G. Figdor, Elizabeth Bock. Dieter Bitter-Suermann. and Rob J. A. M. Michalides. * 1107 Prolongation of Serum Half-Life of Interleukin 2 and Augmenta tion of Lymphokine-activated killer...

full text

Boron Neutron Capture Therapy for Breast Cancer

in 1960’s, but showed little development, as the thermal and epithermal neutron sources were not economical. Nuclear reactors, and recently cyclotrons are being used as neutron sources, thus enabling its widespread utilization (1). Gamma rays are utilized for the irradiation of tumor tissues, and fractional doses up to 50-60 Gray required for tumor ablation in conventional radiation therapy. Su...

full text

Boron Neutron Capture Therapy

A project aimed at the development of an accelerator facility devoted to Boron Neutron Capture Therapy (BNCT) is ongoing at the National Atomic Energy Commission of Argentina [1]. In a first stage of development, the accelerator will be capable of delivering proton or deuteron beams of 30 mA at about 1.4 MeV which is suitable for neutron production through the 9Be(d,n) reaction. In this context...

full text

Boron Neutron Capture Therapy Treatment Planning Improvements

The Boron Neutron Capture Therapy (BNCT) treatment planning process of the Harvard/MIT team used for their clinical Phase I trials is very time consuming. If BNCT proves to be a successful treatment, this process must be made more efficient. Since the Monte Carlo treatment planning calculations were the most time consuming aspect of the treatment planning process, requiring more than thirty six...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 15  issue None

pages  1- 13

publication date 2017-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023